866-997-4948(US-Canada Toll Free)

Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Published By :

DelveInsight

Published Date : Feb 2015

Category :

Ovarian Cancer

No. of Pages : N/A

 

DelveInsight’s, “Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Ovarian Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Metastatic Ovarian Cancer. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Metastatic Ovarian Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturersacross the globe coveringDrug Master FilingsofUS, Europe and API Manufacturers in Asia specifically China and India. The researchanalysis also presents the global sales forecasts data till 2016.

 

DATA SOURCES

 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

 

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

 

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

SCOPE:

 

  • A snapshot of the global Market therapeutics scenario for Metastatic Ovarian Cancer.
  • A review of the marketed products under prescription for Metastatic Ovarian Cancer, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for Metastatic Ovarian Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for Metastatic Ovarian Cancer drugs in the United States, Europe and Asian Regions with location details.
  • Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic Ovarian Cancer drugs.
  • Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Ovarian Cancer drugs.
  • Coverage of Metastatic Ovarian Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
  • Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
  • Key discontinued Marketed products.
  • Global Sales Figure from 2012-2016.

 

REASONS TO BUY

 

  • Evaluate the marketing status and exclusivity details of Metastatic Ovarian Cancerkey products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for Metastatic Ovarian Cancer.
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Ovarian Cancer.
  • API intelligence over marketed drugs forMetastatic Ovarian Cancerand gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline drugs.
  • Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
  • Understanding the scope of the Phase III Drugs with nil regulatory filings.
  • Understanding the chemical route of synthesis of approved drugs for Metastatic Ovarian Cancer.
  • Uncovering opportunities in the rapidly growing US market.

Table of Content

 

Indication Overview

Marketed Drugs

Marketed Details of Drugs by Application Type

Marketed Details of Drugs (NDA) by Marketing Status

Marketed Details of Drugs by Patent Expiration Timeline

Active Pharmaceutical Ingredient (API) Manufacturers Assessment

API Manufacturers by United States Drug Master File (US DMF) Status

API Manufacturers by US DMF Status (Drug Specific)

API Manufacturers in Europe by Country

API Manufacturers in India by State

API Manufacturers in China by Province

Marketed Details of Approved Drugs by Geography

Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs

API Manufacturers by US DMF Status (Drug Specific)

Drugs Market Data and Forecasted Sales Figure (2012-2016)

Marketed Drugs for Metastatic Ovarian Cancer

Drug Name

Drug Description

Global Active Pharmaceutical Manufacturers for Drug

Approval Status of Drug

Patent and Exclusivity Details for Drug

Company Profile and Financials

Phase III Drugs for Metastatic Ovarian Cancer

United States Drug Master File (DMF)

Discontinued Drugs for Metastatic Ovarian Cancer

 

Appendix

Methodology

Contact Us

Disclaimer

List of Table

 

Metastatic Ovarian Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2015

Metastatic Ovarian Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015

Metastatic Ovarian Cancer Therapeutic Market, US, (Year), 2015

Metastatic Ovarian Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2015

Metastatic Ovarian Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers, Europe by Country, 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers, India by State, 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers, China by Province, 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers by Geography 2015

Metastatic Ovarian Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2015

Metastatic Ovarian Cancer Therapeutic Market, Global Sales 2012-2016 (in million USD)

API Manufacturers for Drug, 2015

Phase III Drugs for Metastatic Ovarian Cancer, 2015

Discontinued Drugs for Metastatic Ovarian Cancer, 2015

List of Chart

 

Metastatic Ovarian Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015

Metastatic Ovarian Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015

Metastatic Ovarian Cancer Therapeutic Market, US, (Year), 2015

Metastatic Ovarian Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2015

Metastatic Ovarian Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers, Europe by Country, 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers, India by State, 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers, China by Province, 2015

Metastatic Ovarian Cancer Drugs, API Manufacturers by Geography 2015

Metastatic Ovarian Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2015

Metastatic Ovarian Cancer Therapeutic Market, Global Sales 2012-2016 (in million USD)

Drug, Patent/Exclusivity Expiry (Year), 2015

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *